Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

ZNTL has been the subject of a number of other reports. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research report on Monday, August 12th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $3.05 on Friday. The stock has a market capitalization of $217.34 million, a price-to-earnings ratio of -1.22 and a beta of 1.74. Zentalis Pharmaceuticals has a 1 year low of $2.66 and a 1 year high of $18.07. The business’s 50 day simple moving average is $3.42 and its 200-day simple moving average is $5.33.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, sell-side analysts expect that Zentalis Pharmaceuticals will post -2.76 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Anfield Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $40,000. Erste Asset Management GmbH acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Aigen Investment Management LP purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $41,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth approximately $189,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.